Brief: Medipharm Labs Signs Manufacturing And Ip Licensing Agreement With Biopharmaceutical Leader Avicanna
14/05/2020 11:38
May 14 (Reuters) - Medipharm Labs Corp LABS.TO :
* MEDIPHARM LABS SIGNS WIDE-RANGING STRATEGIC MANUFACTURING
AND IP
LICENSING AGREEMENT WITH BIOPHARMACEUTICAL LEADER AVICANNA INC.
Source text for Eikon: ID:nGNX7jJzZw
Further company coverage: LABS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medipharm Labs
See all newsCanada's MediPharm Labs Q2 revenue rises 11% on international growth
Brief: MediPharm Labs Q2 Revenue CAD 10 Million
Canada's MediPharm Labs reports positive Q1 adjusted EBITDA
Canada's MediPharm Labs FY revenue rises 8% on international sales
Brief: Medipharm Labs Reports Full Year & Fourth Quarter 2025 Results With Over 40% Annual Growth In International Medical Revenue